Replies to post #376 on Immune Pharmaceuticals Inc (fka IMNPQ)

[Investor100]

Immune Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016

https://finance.yahoo.com/news/immune-pharmaceuticals-present-jmp-securities-120600041.html

Dr. Daniel Teper, CEO of Immune, will provide an overview of the Company's business and 2016-17 expected milestones, including updates on:

- The advancement of the two Phase 2 clinical trials in bullous pemphigoid, and orphan auto-immune skin disease, and in ulcerative colitis with bertilimumab, a fully human monoclonal antibody targeting eotaxin-1, a key regulator of immuno-inflammation and,

- The company's immuno-oncology pipeline with a focus on new data and strategy for Ceplene®, a type of immune check-point inhibitor in development in combination with low dose SC Proleukin® for the maintenance of remission in patients with Acute Myeloid Leukemia.

The presentation will be webcast and available on our website (www.immunepharma.com) after the conference.

Investor 100